Results 31 to 40 of about 61,972 (223)

Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab

open access: yesOncoImmunology, 2017
A heavily pretreated patient with triple negative breast cancer distinguished by cutaneous metastases received p53MVA vaccine in combination with pembrolizumab.
Yuan Yuan   +11 more
doaj   +1 more source

LATENT VACCINIA. [PDF]

open access: yesThe Lancet, 1902
n ...
openaire   +2 more sources

A new inhibitor of apoptosis from vaccinia virus and eukaryotes. [PDF]

open access: yes, 2007
A new apoptosis inhibitor is described from vaccinia virus, camelpox virus, and eukaryotic cells. The inhibitor is a hydrophobic, multiple transmembrane protein that is resident in the Golgi and is named GAAP (Golgi anti-apoptotic protein).
Hollinshead, M   +25 more
core   +2 more sources

Vaccinia Virus Infection Requires Maturation of Macropinosomes. [PDF]

open access: yes, 2015
The prototypic poxvirus, vaccinia virus (VACV), occurs in two infectious forms, mature virions (MVs) and extracellular virions (EVs). Both enter HeLa cells by inducing macropinocytic uptake.
Mercer, Jason   +13 more
core   +1 more source

Dairy production practices and associated risks for bovine vaccinia exposure in cattle, Brazil

open access: yesNew Microbes and New Infections, 2017
A cross-sectional serosurvey was performed to identify environmental features or practices of dairy farms associated with risk for exposure to vaccinia-like viruses in dairy cattle in Brazil.
I.A. Borges   +10 more
doaj   +1 more source

Recombinant chimeric horsepox virus (TNX-801) is attenuated relative to vaccinia virus strains in both in vitro and in vivo models

open access: yesmSphere
Recombinant chimeric horsepox virus (TNX-801) is a preclinical vaccine in development against mpox and smallpox. In this report, we investigated the potential phenotypic differences in in vitro and in vivo models between TNX-801 and older vaccinia virus (
Stephanie V. Trefry   +17 more
doaj   +1 more source

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

open access: yesViruses, 2015
The last few years have seen an increased interest in immunotherapy in the treatment of malignant disease. In particular, there has been significant enthusiasm for oncolytic virotherapy, with a large amount of pre-clinical data showing promise in animal ...
Samantha Turnbull   +5 more
doaj   +1 more source

In-vitro demonstration of cell-mediated immunity to vaccinia virus in man [PDF]

open access: yes, 1975
Cell mediated immunity to vaccinia virus in man was studied by lymphocyte transformation. Vaccinia antigen, propagated on BHK-21 and Vero cells, could be used successfully for in-vitro testing after partial purification as well as crude infectious ...
Koszinowski, Ulrich H.   +2 more
core   +1 more source

Remaining Questions about Clinical Variola Major

open access: yesEmerging Infectious Diseases, 2011
After the recent summary of World Health Organization–authorized research on smallpox, several clinical issues remain. This policy review addresses whether early hemorrhagic smallpox is disseminated intravascular coagulation and speculates about the ...
J. Michael Lane
doaj   +1 more source

SMALLPOX AND VACCINIA. [PDF]

open access: yesJAMA: The Journal of the American Medical Association, 1907
In an experience with smallpox limited to the town of Colorado and occurring between the dates of April 7 and May 20, 1907, the following conditions were encountered. They are interesting as confirming previous observations as to the coincidence of variola and vaccinia.
openaire   +1 more source

Home - About - Disclaimer - Privacy